Drugs / VGA039
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05776069 | Mar 2023 → Dec 2029 expected | von Willebrand disease (hereditary or acquired) | Vega Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07115004 | Oct 2025 → Oct 2028 expected | von Willebrand disease (hereditary or acquired) | Vega Therapeutics, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Incyte Corporation | Results Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types incyte.com ↗
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Incyte Corporation | Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types incyte.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGA039 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05776069 ↗ |
| Route | Intravenous | “evaluate intravenous (IV) and subcutaneous (SC) VGA039” NCT05776069 ↗ |
| Route | Subcutaneous | “evaluate intravenous (IV) and subcutaneous (SC) VGA039” NCT05776069 ↗ |